Cargando…

Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report

Pancreatic carcinoma is the leading cause of death among digestive malignancies in China. In particular, there is no breakthrough in prolonging the survival of pancreatic cancer patients with chemical and targeted therapies. Tumor immunotherapy brings opportunities and progress for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Chen-Xu, Zhao, Yu, Qian, Hong, Fu, Hui, Yan, Yu-Ying, Qiu, Yu-Shuang, Zhou, Can-Can, Huang, Fang, Shen, Fu-Ming, Li, Dong-Jie, Xu, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894891/
https://www.ncbi.nlm.nih.gov/pubmed/36744247
http://dx.doi.org/10.3389/fphar.2023.1121122
_version_ 1784881830564986880
author Ni, Chen-Xu
Zhao, Yu
Qian, Hong
Fu, Hui
Yan, Yu-Ying
Qiu, Yu-Shuang
Zhou, Can-Can
Huang, Fang
Shen, Fu-Ming
Li, Dong-Jie
Xu, Qing
author_facet Ni, Chen-Xu
Zhao, Yu
Qian, Hong
Fu, Hui
Yan, Yu-Ying
Qiu, Yu-Shuang
Zhou, Can-Can
Huang, Fang
Shen, Fu-Ming
Li, Dong-Jie
Xu, Qing
author_sort Ni, Chen-Xu
collection PubMed
description Pancreatic carcinoma is the leading cause of death among digestive malignancies in China. In particular, there is no breakthrough in prolonging the survival of pancreatic cancer patients with chemical and targeted therapies. Tumor immunotherapy brings opportunities and progress for the treatment of pancreatic cancer. Sintilimab is an innovative PD-1 inhibitor which was reported certain clinical benefits in multi-line treatments of advanced pancreatic cancer with gemcitabine. The combination therapy of PD-1 with gemcitabine plus high-intensity focused ultrasound (HIFU) in pancreatic cancer has not been reported. Here we report a case of a Chinese old patient diagnosed with metastatic pancreatic cancer. Two months after sintilimab treatment, the patient occurred severe immune colitis. The patient was diagnosed with immune ureteritis after 8 months of treatment. The immue-related adverse events (irAEs) refined after timely recognition and correct intervention by the clinician and clinical pharmacist. After first-line treatment of sintilimab plus gemcitabine combined with pancreatic HIFU, the patient achieved a remarkable benefit of 11-month progression-free survival (PFS) and 20-month overall survival (OS). The first-line treatment of sintilimab plus gemcitabine combined with HIFU demonstrates a potential therapeutic effect on metastatic pancreatic carcinoma with tolerable adverse reactions.
format Online
Article
Text
id pubmed-9894891
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98948912023-02-04 Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report Ni, Chen-Xu Zhao, Yu Qian, Hong Fu, Hui Yan, Yu-Ying Qiu, Yu-Shuang Zhou, Can-Can Huang, Fang Shen, Fu-Ming Li, Dong-Jie Xu, Qing Front Pharmacol Pharmacology Pancreatic carcinoma is the leading cause of death among digestive malignancies in China. In particular, there is no breakthrough in prolonging the survival of pancreatic cancer patients with chemical and targeted therapies. Tumor immunotherapy brings opportunities and progress for the treatment of pancreatic cancer. Sintilimab is an innovative PD-1 inhibitor which was reported certain clinical benefits in multi-line treatments of advanced pancreatic cancer with gemcitabine. The combination therapy of PD-1 with gemcitabine plus high-intensity focused ultrasound (HIFU) in pancreatic cancer has not been reported. Here we report a case of a Chinese old patient diagnosed with metastatic pancreatic cancer. Two months after sintilimab treatment, the patient occurred severe immune colitis. The patient was diagnosed with immune ureteritis after 8 months of treatment. The immue-related adverse events (irAEs) refined after timely recognition and correct intervention by the clinician and clinical pharmacist. After first-line treatment of sintilimab plus gemcitabine combined with pancreatic HIFU, the patient achieved a remarkable benefit of 11-month progression-free survival (PFS) and 20-month overall survival (OS). The first-line treatment of sintilimab plus gemcitabine combined with HIFU demonstrates a potential therapeutic effect on metastatic pancreatic carcinoma with tolerable adverse reactions. Frontiers Media S.A. 2023-01-20 /pmc/articles/PMC9894891/ /pubmed/36744247 http://dx.doi.org/10.3389/fphar.2023.1121122 Text en Copyright © 2023 Ni, Zhao, Qian, Fu, Yan, Qiu, Zhou, Huang, Shen, Li and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ni, Chen-Xu
Zhao, Yu
Qian, Hong
Fu, Hui
Yan, Yu-Ying
Qiu, Yu-Shuang
Zhou, Can-Can
Huang, Fang
Shen, Fu-Ming
Li, Dong-Jie
Xu, Qing
Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report
title Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report
title_full Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report
title_fullStr Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report
title_full_unstemmed Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report
title_short Long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: A case report
title_sort long survival in a pancreatic carcinoma patient with multi-organ toxicities after sintilimab treatment: a case report
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894891/
https://www.ncbi.nlm.nih.gov/pubmed/36744247
http://dx.doi.org/10.3389/fphar.2023.1121122
work_keys_str_mv AT nichenxu longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport
AT zhaoyu longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport
AT qianhong longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport
AT fuhui longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport
AT yanyuying longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport
AT qiuyushuang longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport
AT zhoucancan longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport
AT huangfang longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport
AT shenfuming longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport
AT lidongjie longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport
AT xuqing longsurvivalinapancreaticcarcinomapatientwithmultiorgantoxicitiesaftersintilimabtreatmentacasereport